Navigation Links
LA BioMed research finds simpler way to assess breast cancer risk
Date:11/13/2007

TORRANCE (Nov. 13, 2007) - A new, simpler model for predicting breast cancer risk in postmenopausal women appears to be as accurate as a more complicated method currently used to decide if women would benefit from medication to reduce their risk of getting cancer, according to research published today in the Journal of the National Cancer Institute.

A team of researchers led by Rowan T. Chlebowski, a lead investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), sought a simpler method for measuring breast cancer risk so women and their doctors could easily determine when the women would be likely to benefit from tamoxifen treatment for reducing their chances of getting breast cancer.

"For the first time, a postmenopausal woman can use a simple model and determine by herself if she is at increased risk of getting breast cancer, said Dr. Chlebowski. She could then raise this issue with her health care provider because interventions to reduce her risk of breast cancer are now available."

Using data from the Womens Health Initiative, a 15-year research program involving 161,808 postmenopausal women and funded by the National Institutes of Health, the researchers found postmenopausal women were at an increased risk of developing breast cancer if they were: 55 years of age or older and had either had a breast biopsy at any time, regardless of findings, or had a first-degree relative (mother, sister or daughter) who had breast cancer diagnosed at any age.

"Increased risk" is defined as about a 2 percent risk of developing breast cancer over the next five years. The researchers sought a quicker and easier way to determine risk because those who are at increased risk may benefit from tamoxifen treatment to reduce their chances of getting breast cancer.

Prior to this study, most physicians relied on the Gail Model to determine risk. But it involves so many variables that a c
'/>"/>

Contact: Laura Mecoy
lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
2. Biomedtex Inc. Announces A. Marc Rocca as President and CEO
3. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
4. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
5. BioMed Realty Trust to Report 2007 Third Quarter Results
6. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
7. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
8. BioMed Realty Trust Reports Third Quarter 2007 Financial Results
9. Stanford researchers find culprit in aging muscles that heal poorly
10. Children of depressed moms do better when dad is involved, SLU researcher finds
11. UCLA researchers identify markers that may predict diabetes in still-healthy people

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...ARP Praises House Passage of Health Care Reform Bi...edicare, improve coverage for all Americans ,,... -- ,, SUMMARY: Last night the United States...are reform legislation that would strengthen Medic...e companies that prices millions of Americans out ...
(Date:11/8/2009)... pain now can take you out of the game later, doct...ws) -- Foot injuries are the talk of the NFL this ...anning and running back Willie Parker. , Offici...and American Academy of Podiatric Sports Medicine ...en they play fall sports like football and lacross...
(Date:11/8/2009)...SHINGTON, Nov. 7 Tonigh...le Health Care for America Act, landmark health re...as access to quality, affordable, stable and secur...cks down on some of the insurance industry,s worst...ericans and cut the deficit by $104 billion over t...
(Date:11/8/2009)... Freeze-drying of biopharmaceutic...auga, Ontario facility. , ...ellner, President and CEO of Therapure Biopharma I...ivery of a commercial scale pharmaceutical grade f...reeze drying (lyophilization) available for contra...
(Date:11/8/2009)...SHINGTON, Nov. 7 Today,...itts, Kaptur, Dahlkemper, Smith, Ellsworth and Lip... America Act" (H.R. 3962). The amendment maintains...for abortion and for benefits packages that includ...ose who receive affordability credits and those wh...
Breaking Medicine News(10 mins):Health News:AARP Pennsylvania Key Vote News Alert 2Health News:AARP Pennsylvania Key Vote News Alert 3Health News:AARP Pennsylvania Key Vote News Alert 4Health News:Rx for Fall Foot Injuries 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2
... at treating female alcoholics than traditional me... researchers// at RTI International; University o... University. The study, published in the Jour... Researchers found that women alcoholics treat...
...uffer from stress urinary incontinence (SUI), a co...can lead to urine leakage.// “We try to trea...arning better bladder habits, doing Kegel exercise...D., a urologist on the medical staff at Baylor Wax...
...al says that UK recommendations for the availabili...launted.// In September 1998, new legislation was ...paracetamol, which were responsible for 200 deaths... to a maximum of 32 tablets of 500 mg each in phar...
...a heart attack, according to new research from Uni... is published// in the August edition of the journ...available on line at http://www3.interscience.w... be at risk for heart attack due to gout. Go...
...y the stem cells researchers across the world and ...al Research (BIMR)and Illumina Inc., it was found ...racteristics which make it pluripotent and totipot...sed or damaged cells with healthy cells. The study...
... University of California-Davis and Justus-Liebig ...ments //could be possible for autism and Parkinson...ed their attention despite being distracted using ...tic methods, treatments and cures is severely hind...
Other Medicine News:Health News:Marital Therapy Effective Treatment for Female Alcoholics 2Health News:UK Recommendations On Painkillers Flaunted 2Health News:Risk Of Heart Attack Increased By Gout 2Health News:Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning 2Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 2Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 3
(Date:11/6/2009)...,, SAN DIEGO, Nov. 6 ...company focused on developing products for minimal...nnounced today the appointment of Michael J. Lambe... Officer, effective November 9, 2009. The Company... Team updates. ,, "Michael will be an excellent...
(Date:11/6/2009)...,, SAN DIEGO, Nov. 6 ...hnology company focused on the development of smal... cancer and human immunodeficiency virus (HIV), to...results for the third quarter and nine months ende...ewscom.com/cgi-bin/prnh/20091104/ARDEALOGO ) ,,...
(Date:11/6/2009)...,, SAN DIEGO, Nov. 6 NexBio Inc... for Disease Control and Prevention (CDC), St. Lou...nounced today the publication of two articles in t...ished studies suggest that DAS181 (Fludase ® ...eatment and prevention of the Pandemic Influenza A...
Breaking Medicine Technology:NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Government Stops Unlawful Social Security Suspensions 3B Agrees to Repay More Than Half a Billion in Back Benefits 54271 1Government Stops Unlawful Social Security Suspensions 3B Agrees to Repay More Than Half a Billion in Back Benefits 54271 2Schering Plough Announces Resolution of Litigations on U S Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX 28R 29 54268 1Schering Plough Announces Resolution of Litigations on U S Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX 28R 29 54268 2Schering Plough Announces Resolution of Litigations on U S Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX 28R 29 54268 33SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 13SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 23SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 33SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 43SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 53SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 63SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 73SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 83SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 93SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 103SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 113SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 123SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 133SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 143SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 153SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 163SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 173SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 183SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 193SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 203SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 213SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 223SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 233SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 243SBio Inc Announces Unaudited Second Quarter 2009 Results 54264 25
TME 62 TS
...(RAM) is the first visual examination device that ... ACUITY in eyes with glaucoma, cataract, and macul..., and can test each eye easily in under 60 seconds...olumbia University in New York City, the RAM can h...
... components for individual indications. XCaliber c... Made of an innovative composite plastic material,...only much lighter. This means it's easier to handl...atient. ,Come pre-assembled, packaged sterile, and...
...ated with displaced pelvic fractures is one of the... trauma surgeons. , ,Recognizing the difficult...ternal fixation, and internal fixation in these ty... developed as a method to provide emergent reducti...
Medicine Products: